Back to search results

Thiamine Intervention for Coronary Artery Bypass Grafting

This study is looking at whether giving thiamine (a type of vitamin B1) can help reduce thinking and memory problems after coronary artery bypass grafting (CABG) surgery. You might be able to join if you have coronary heart disease (CHD), are scheduled for CABG, are between 60 and 80 years old, have a thiamine deficiency, and meet other criteria. Participants will receive either an infusion of thiamine or a placebo (an inactive substance). Researchers will measure your blood levels of thiamine, lactate, and inflammation to see if thiamine helps. The study's status is currently unclear.

Study design
This is a double-blind, randomized study with two groups, involving 52 participants. This means neither you nor the study team will know if you are receiving thiamine or the placebo.
What's involved
You will undergo cognitive assessments and have your blood levels of thiamine, lactate, and inflammatory markers evaluated at the beginning of the study and one month after your CABG surgery.
Compensation
Not stated in the trial record.
Follow-up
Your blood levels will be measured at baseline and again one month after your CABG surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06326996

Thiamine Intervention and Coronary Artery Bypass Grafting

Recruiting
EARLY_PHASE1Ages 60–80InterventionalTreatment
University of California, Los Angeles
~52 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:ThiaminePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effects of thiamine treatment intervention on blood lactate levels.
Measured over Baseline and after 1 month after CABG.
+11 more outcomes measured

Conditions

Coronary Heart Disease
Coronary Artery Bypass Grafting

Explore related trials

Coronary heart disease

NCT06326996

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UCLA

    Los Angeles, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Rajesh Kumar, PhD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

Rajesh Kumar, PhD
[email protected]
310-206-1699
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)
Thiamine deficiency before CABG
European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \>1.5%
Off-pump surgery

Exclusion

Dementia at baseline \[Montreal Cognitive Assessment (MoCA) \<21 within 5 days before CABG\]
Current in-take of thiamine
Known thiamine allergy
Uncontrolled blood glucose levels
Unable to give consent due to illness
History of hyperlactatemia
Recent (within several years and/or up to the judgment of the PI/co-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and/or concussion)
Stroke
Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)
Patients with history of alcohol or substance abuse
Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)
Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)
Chronic immunodeficiency (including HIV)
Congenital brain deficits will also be excluded

What this trial measures

  • Effects of thiamine treatment intervention on blood lactate levels.Baseline and after 1 month after CABG.

    Assess thiamine treatment effect on blood lactate levels in CABG patients with and without intervention measured via blood gas analyzer (ABL90 flex plus, Radiometer).

  • Effects of thiamine treatment intervention on blood thiamine levels.Baseline and after 1 month after CABG.

    Assess thiamine treatment effect on blood thiamine levels in CABG patients with and without intervention measured via blood gas analyzer (ABL90 flex plus, Radiometer).

  • Effects of thiamine treatment intervention on blood inflammatory levels.Baseline and after 1 month after CABG.

    Assess thiamine treatment effect on blood inflammatory levels in CABG patients with and without intervention measured via a custom kit, including cytokines from the human 38-plex magnetic cytokine/chemokine kit, will be used per manufacturer's instructions.

  • Evaluate cognitive function in CABG patients with thiamine treatment.Baseline and after 1 month after CABG.

    The investigators will evaluate cognitive function using the NIH Toolbox Cognition Battery (executive function, attention, and speed). CABG patients with thiamine treatment will show a change in cognition over CABG patients without thiamine treatment.

  • Evaluate long term effects of thiamine treatment intervention on cognitive function in CABG patients with thiamine treatment.6 months after CABG.

    The investigators will evaluate cognitive function using the NIH Toolbox Cognition Battery (executive function, attention, and speed). CABG patients with thiamine treatment will show a change in cognition over CABG patients without thiamine treatment.

  • Examine cognition in CABG patients with thiamine treatment.Baseline and 1 month after CABG.

    The investigators will examine cognition using the Wide Range Assessment of Memory and Learning 2 (WRAML2). CABG patients with thiamine treatment will show a change in cognition over CABG patients without thiamine treatment.

  • Examine long term effects of thiamine treatment intervention on cognition in CABG patients with thiamine treatment.6 months after CABG.

    The investigators will examine cognition using the Wide Range Assessment of Memory and Learning 2 (WRAML2). CABG patients with thiamine treatment will show a change in cognition over CABG patients without thiamine treatment.

  • Cognition assessment in CABG patients after thiamine treatment.Baseline and 1 month after CABG.

    The investigators will assess cognition using the Montreal Cognitive Assessment (MoCA). CABG patients with thiamine treatment will show a change in cognition over CABG patients without thiamine treatment. The MoCA is a brief cognitive assessment administered to the participant by the investigator. The score ranges from 0 to 30, with higher scores indicating better cognitive function.

  • Assessment of long term effects of thiamine treatment intervention on cognition in CABG patients after thiamine treatment.6 months after CABG.

    The investigators will assess cognition using the Montreal Cognitive Assessment (MoCA). CABG patients with thiamine treatment will show a change in cognition over CABG patients without thiamine treatment. The MoCA is a brief cognitive assessment administered to the participant by the investigator. The score ranges from 0 to 30, with higher scores indicating better cognitive function.

  • Long term effect of thiamine treatment intervention on quality of life.6 months after CABG.

    Examine the long-term quality of life in older CHD subjects with and without thiamine intervention treatment as measured by NIH validated Short-Form 36 (SF-36) survey. The SF-36 is a 36 question form filled out by the participant and scored by the investigator. The score ranges from 0 to 100, with higher scores indicating better health status.

  • Long term effect of thiamine treatment intervention on daily activities using PASE.6 months after CABG.

    Examine the long-term daily activities status in older CHD subjects with and without thiamine intervention treatment as measured by NIH validated Physical Activity Scale for the Elderly (PASE). PASE is a brief self-administered questionnaire measuring physical activity which generates a score, ranging from 0 to 793, with higher scores indicating greater physical activity.

  • Long term effect of thiamine treatment intervention on daily activities using PPA.6 months after CABG.

    Examine the long-term daily activities status in older CHD subjects with and without thiamine intervention treatment as measured by Paffenbarger Physical Activity (PPA).